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Abstract 
Somatostatin (SS) is an inhibitory tetradecapeptide 
hormone with exocrine, endocrine, paracrine, and 
autocrine activities, which plays an important 
regulatory role in several cell functions, including 
inhibition of endocrine secretion and cell proliferation. 
Most of the effects of SS and of its currently available 
analogs are mediated via five different G protein-
coupled receptor (GPCRs), codenamed sst1-5. SS 
receptors (ssts) are expressed in a tissue- and subtype-
selective manner in both normal and neoplastic cells, 
and the majority of SS target tissues express multiple 
ssts. Recent data suggest that when ssts are coexpressed, 
they may interact forming homo- and hetero-dimers 
also with other GPCRs, thus altering their original 
pharmacological and functional profiles. The formation 
of dimers can be not only constitutive, but also ligand-
promoted: hence, compounds with high affinity for the 
different receptor subtypes can be used to achieve 
effects elicited by specific dimers. A feature common 
to most GPCRs is the cyclic process of signaling, 
desensitization, internalization, resensitization, and 
recycling to the plasma membrane. These events 
prevent cells from undergoing excessive receptor 
stimulation or periods of prolonged inactivity. SS 
receptors differently internalize after agonist binding 
and, specifically, sst2, sst3 and sst5 are internalized to a 
greater extent than sst1 or sst4. ssts are linked to several 
second messenger systems which are involved in their 
downstream intracellular response (i.e., adenylyl 
cyclase, calcium and potassium ion channels, Na+/H+ 
antiporter, phospholipase C, phospholipase A2, 
mitogen activated protein kinase, NO/cGMP, and 
serine-, threonine, and phosphotyrosyl- protein 
phosphatase). 
Interestingly, SS and SS analogs can control tumor 
development and progression/metastatization by direct 
actions, mediated by the ssts, and indirect actions, 
independent of receptor involvement. The direct 
antiproliferative effects include inhibition of 
autocrine/paracrine growth-promoting hormone/growth 
factor synthesis, arrest of cell division (by blockade of 
growth factor-mediated mitogenic signals), suppression 
of cell invasion and induction of apoptosis 
(programmed cell death). Indirect antitumor effects of 
SS include suppression of synthesis or/and release of 
growth factors and growth-promoting hormones, such 
as insulin, prolactin, insulin like-growth factor 1, 
epidermal growth factor, transforming growth factor-, 
gastrin, cholecystokinin and growth hormone. A 
specific pattern of ssts activation thus seems to elicit 
relevant antitumoral actions and deserves further 
exploitation with the aim of validating novel 
therapeutic approaches to cancer. 
1. Somatostatin 
Somatostatin (SS) was first identified in the ovine 
hypothalamus as a tetradecapeptide that inhibited the 
release of growth hormone (Brazeau et al., 1973). SS-
producing cells are present at high densities throughout 
the central and peripheral nervous systems. In the 
periphery, SS is also secreted by pancreas and gut and 
in a lesser extent by thyroid, adrenals and 
submandibular glands, kidneys, prostate, and placenta 
(Polak et al., 1975). SS mediates a variety of biological 
effects, the most  
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Figure 1. Amino acid sequences of the human prosomatostatin. 
 
important occurring at the pituitary (inhibition of 
growth hormone (GH) and tireotropic stimulating 
hormone (TSH) secretion) and gastroenteropancreatic 
(GEP) levels (inhibition of insulin, glucagon, and 
secretin secretion; inhibition of hydrochloric acid 
production and intestinal fluid absorption) (Konturek et 
al., 1976). In addition to inhibition of hormone 
secretion, SS also shows antiproliferative and anti-
angiogenetic properties, that have been largely 
investigated both in cell lines (i.e., human prostate 
cancer cells, human non small lung cell carcinomas and 
pituitary adenomas) and GH-secreting tumors. The SS 
form originally identified in the hypothalamus was SS-
14, while SS-28, a congener of SS-14 extended at the 
N-terminus, was discovered subsequently (Shen et al., 
1982). The single human SS gene is located on 
chromosome 3q28 and the correlate SS mRNA codes 
for a 116-amino acids (aa) prepro-SS protein (MW 
12,727 Da). Prepro-SS has a sequence of hydrophobic 
aa at the N-terminus which is cleaved at the gly-ala 
junction at position -78 (from the N-terminus to the C-
terminus). Pro-SS undergoes both monobasic (Arg-15) 
and dibasic (Arg-2Lys-1) cleavages to release the two 
biofunctional hormones SS-28 and SS-14 (Funckes et 
al., 1983; Brakch et al., 2002) (Figure 1). 
2. Somatostatin receptors 
In mammals, the biological actions of SS are mediated 
by at least six G protein-coupled SS receptors (sst) 
encoded by five different genes, named sst1-sst5. Sst2 
exists in two splice variants, sst2A (a long form) and 
sst2B (a short form), which differ only in the length of 
the cytoplasmic tail. Sst2 displays a cryptic intron at the 
3' end of the coding region, which gives rise to the two 
spliced variants (Baumeister and Meyerhof, 2000; 
Olias et al., 2004). In the human gene, the spliced exon 
encodes for 25 aa residues compared to 38 residues in 
the unspliced form. The encoded receptor proteins 
range in size from 356 to 391 aa residues, showing the 
greatest sequence similarity in the putative 
transmembrane region, and diverge at their N- and C-
terminal segments (Patel, 1999). Human ssts genes are 
localized to chromosome 14q13 (sst1), 17q24 (sst2), 
22q13.1 (sst3), 20p11.2 (sst4), and 16p13.3 (sst5) 
(Yamada et al., 1993) encoding for proteins of 391 aa, 
369 aa, 418 aa, 388 aa, and 363 aa, respectively 
(Yamada et al., 1992; Corness et al., 1993; Rohrer et 
al., 1993; Panetta et al., 1994). Structurally, those 
receptors belong to the so-called "superfamily" of G 
protein-coupled receptors (GPCRs). All sst isoforms 
possess a highly conserved sequence motif, 
YANSCANPI/VLY, in the seventh transmembrane 
region, which serves as a signature sequence for this 
receptor family (Kreienkamp et al., 2002). On the other 
hand, genes for sst1, 3, 4, and sst5 lack classical introns. 
Interestingly, the estimated sequence identity between 
sst1 and sst2 receptors is 46%. The deduced aa sequence 
of human sst3 receptors displays the following degrees 
of similarity with other members of the sst family: 62% 
(sst1), 64% (sst2), and 58% (sst4). Moreover, four ssts 
have been identified in fish and variant forms of several 
ssts also exist: sst3a, sst3b, sst5a, sst5b, and sst5c in 
goldfish (Canosa et al., 2004), and sst1a and sst1b in 
trout (Slagter and Sheridan, 2004). As was the case 
with SS genes, phylogenetic analysis suggests that sst 
genes appear to have arisen from a series of gene 
duplication events. 
2.1 Homo- and hetero-dimerization of somatostatin 
receptor subtypes 
When ssts in the cell membrane are coexpressed, they 
may interact forming homo- and hetero-dimers also 
with other GPCRs, thus altering their original 
pharmacological and functional profiles. A series of 
studies, carried out on transfected cell lines, have 
shown that dimers can consist of two identical sst 
subtypes (homodimers) or two different subtypes 
(heterodimers), with a range of possible combinations 
depending on the specific subtype and, probably, on the 
specific sst-expressing population (Baragli et al., 2007). 
The five SS receptor isoforms can be involved in the 
formation of different dimers, namely, sst1 and sst5 bind 
efficiently together, while stable sst4-sst5 dimers have 
not been observed. These interactions are capable to 
provide greater signalling diversity, affecting the 
downstream intracellular effects mediated by receptor 
activation, such as ligand binding affinity, agonist-
induced regulation and trafficking. In fact, sst1 
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endocytosis is enhanced when sst1 and sst5 are co-
expressed in the same cell and sst5 is activated; 
conversely, the internalization of sst2 is delayed by sst5 
and sst2 co-expression. Moreover, ssts can form also 
heterodimers with other GPCRs: sst2 interacts with the 
µ-opioid receptor, and sst5 binds to the D2 dopamine 
receptor (D2R). Interestingly, the sst5-D2R dimer 
enhances the effects of both receptors, leading to a 
more potent inhibition of adenylyl cyclase (AC) 
(Møller et al., 2003). 
The dimer formation can be not only constitutive, but 
also ligand-promoted: hence, compounds with high 
affinity for the different receptor subtypes can be used 
to achieve effects elicited by specific dimers. In the last 
years, a variety of mono-, bi- and pan-specific SS 
analogs has been synthesized, allowing the 
characterization of the intracellular effectors involved 
in the downstream signalling of the different ssts 
(Saveanu et al., 2001). The new receptor specific 
compounds showed to be useful under many aspects; 
among them, the understanding of the synergistic effect 
caused by the simultaneous activation of different 
receptors. In cultured pituitary cells, a sst2-D2R 
chimeric compound (BIM-23A387) showed a more 
potent action in inhibiting prolactin (PRL) and GH 
secretion compared to the related mono-specific 
analogs, either alone or in combination (Ferone et al., 
2007). A similar pattern of action has been observed for 
the anti-secretory and anti-proliferative activity in 
prostate and lung in vitro models, where the treatment 
with the chimeric sst2-sst5 and sst2-sst5-D2R compounds 
were more effective than the respective mono-specific 
SS and D2R analogs (Arvigo et al., 2010). This 
evidence suggests that the concurrent activation of 
different GPCRs triggers their dimerization, leading to 
an enhanced effect. 
2.2 Trafficking of somatostatin receptor subtypes 
A feature common to most GPCRs is the cyclic process 
of signaling, desensitization, internalization, 
resensitization, and recycling to the plasma membrane. 
These events prevent cells from undergoing excessive 
receptor stimulation or periods of prolonged inactivity 
(van Koppen et al., 2004). 
SS receptors differently internalize after agonist 
binding and, specifically, sst2, sst3 and sst5 are 
internalized to a higher extent than sst1 or sst4. Among 
all subtypes, the agonist-mediated trafficking of both 
sst2 splicing isoforms are the mostly described (Jacobs 
and Schulz, 2008). Investigations in neuroendocrine 
tumors showed that both sst2A and sst2B isoforms are 
rapidly desensitized and internalized after agonist-
mediated phosphorylation. Receptor phosphorylation, 
which involves sites located in the third intracellular 
loop and in the C-terminal tail, is followed by 
recruitment of β-arrestin to the receptor forming a 
stable complex, which is internalized into the same 
endocytotic vesicles. Interestingly, the binding affinity 
of the agonist plays an important role in the degree of 
receptor internalization. A high binding affinity of the 
agonist is a prerequisite for triggering sst2 
internalization. In fact, the bi-specific sst2/sst5 analog 
BIM23244, which has a greater sst2 affinity compared 
to L-817/818 analog is able to induce a greater 
internalization (Jacobs and Schulz, 2008). 
Sst5 differs from sst2A in its cellular localization and 
appears to be predominantly located in intracellular 
components even without agonist treatment, whereas 
after stimulation, a large amount of intracellular 
receptors is recruited to the cell surface. The sst5 third 
intracellular (i3) loop and the C-terminal tail have been 
found to regulate receptor internalization, which occurs 
via clathrin-dependent mechanisms. In cultured 
pituitary cell lines, where sst5 underwent different kinds 
of point mutations within the i3 loop, there is a 
reduction of receptor internalization upon SS-28 
treatment. Moreover, by using different C-terminus 
truncated forms of the receptor, an enhanced sst5 
internalization has been observed, thus showing that the 
sst5 C-terminal tail, or at least a part of it, has an 
inhibitory role in receptor internalization (Peverelli et 
al., 2008). 
Sst3, which shows high affinity for SS-14, internalizes 
efficiently after agonist stimulation through a clathrin-
dependent mediated pathway. Without stimulation, sst3 
is almost exclusively located at the plasma membrane, 
whereas after agonist withdrawal only a small amount 
of sst3 is recycled to the cell surface (Peverelli et al., 
2008). 
Hence, due to the differential expression of SS 
receptors in tumors, the comparison of their ability to 
undergo agonist-induced desensitization and 
internalization may provide important clues for the 
clinical use of SS analogs. In this context, an in vitro 
study demonstrated that short-term administration of 
the multiligand (sst1/sst2/sst3/sst5) pasireotide 
(SOM230) modulates SS receptor trafficking in a 
manner clearly distinct from octreotide (sst2/sst5) 
(Tulipano and Schulz, 2007). SOM230 was less potent 
than octreotide in inducing signaling and internalization 
of the sst2 receptor. Whereas octreotide-activated sst2 
receptors cointernalized with β-arrestin-2 into the same 
endocytic vesicles, SOM230-mediated sst2 activation 
led to the formation of unstable complexes that 
dissociated at or near the plasma membrane. Sst2 
receptors recycled faster to the plasma membrane in 
SOM230- than in octreotide-treated cells. The 
accelerated recycling of SOM230-activated receptors 
may counteract homologous desensitization in sst2-
expressing cells and, hence, result in longer lasting 
functional responses of SOM230 (Lesche et al., 2009). 
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Figure 2. Schematic representation of a ligand-driven somatostatin receptor internalization. GRK: GPCR kinase; CCV: clathrin-
coated vesicle (modified from van Koppen et al., 2004). 
 
2.3 Somatostatin receptor signalling pathways 
All five SS isoforms (ssts) bind/interact to G proteins to 
activate their signalling pathways. They couple to all 
three Gi subunits (Gi1, Gi2, and Gi3) leading to a potent 
inhibition of AC activation, and then of cyclic AMP 
(cAMP) synthesis. Specifically, sst1 is coupled to AC 
via Gi3; sst2A is able to associate with Gi1, Gi2, Gi3, and 
Gao2; sst3 interacts with Gi1, Gi2, Gi4, and Gi6 (Reisine 
and Bell, 1995). 
Several second messenger systems are involved in their 
downstream intracellular response: AC, calcium (Ca2+) 
and potassium (K+) ion channels, sodium (Na+)/H+ 
antiporter, phospholipase C (PLC), phospholipase A2 
(PLA2), mitogen activated protein kinase (MAPK), 
NO/cGMP, and serine-, threonine-, and 
phosphotyrosyl-protein phosphatase (PTP) (Patel, 
1999). 
Sst2 and sst4 are the main receptors that activate 
voltage-gated K+ current (Yang and Chen, 2007). As a 
result of their activation, membrane hyperpolarization 
occurs, hindering any subsequent spontaneous 
membrane potential and leading to a reduction in 
intracellular Ca2+. Ssts can differently modify Ca2+ 
currents; in AtT-20 murine cell line, both sst2 and sst5 
can couple negatively to an L-type Ca2+ channel 
reducing Ca2+ influx (Tallent et al., 1996), whereas, 
conversely, in the GH3 rat pituitary tumor cell line, 
only sst2 blocks voltage-gated Ca2+ current (Yang and 
Chen, 2007). 
The human ssts also stimulate PTP through a pertussis 
toxin-sensitive pathway involving Gi2, but differencies 
among the various species have been found, since sst5 
in rat does not regulate PTP. The first evidence of ssts-
mediated activation of PTP was given by the 
counteraction driven by ssts on tyrosine kinase 
receptors-mediated proliferative effect (Florio, 2008a). 
One of the main downstream effects of ssts-mediated 
PTP activation is the inhibition of MAPK ERK1/2 
activity. Several data exist about the inhibition of the 
MAPK signalling cascade by three of the five sst 
subtypes: sst2, sst3 and sst5. In AtT-20 and in 
transfected CHO-K1 cells, sst5 constitutively restrains 
ERK1/2 phosphorylation (Ben-Shlomo et al., 2007), 
and sst2 and sst3 mediated the same inhibitory signal in 
SHSY-5Y neuroblastoma cells and in NIH3T3 cells, 
respectively. Conversely, sst1 and sst4 stimulate the 
MAPK pathway (Patel, 1999). 
Glutamate receptor ion channels are also involved in 
ssts signalling: sst2 inhibits AMPA/kainate receptor-
mediated glutamate currents, while sst1 stimulates 
AMPA/kainate receptor activity in cultured mouse 
hypothalamic neurons. 
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Inositol 1,4,5-trisphosphate (IP3) represents another 
intracellular signalling pathway linked to sst2. In CHO-
DG44 cells, it takes place via sst2-mediated activation 
of phosphatidylinositol 3-kinases (PI3K), whereas in 
astrocytes and in intestinal smooth muscle cells it is 
driven by PLC (Florio, 2008a). Experimental data in rat 
pituitary F4C1 cells indicate that the activation of sst2, 
but not sst1, stimulates PLC activity and increases 
cytosolic Ca2+level, due to Ca2+ release from 
intracellular stores (Rosskopf et al., 2003). 
In hippocampal neurons, SS effect on PLA-2-
dependent stimulation of arachidonate production has 
been associated with sst4, which is able to elicit 
arachidonate synthesis through phospholipase A2 
(PLA-2) activation (Patel, 1999). 
In colon carcinoma, enteric endocrine and hepatic cells, 
the Na+/H+ exchangers can be also activated by sst1, 
sst3 and sst4, but not by sst2 and sst5 (Florio, 2008a). 
Interestingly, in human sst5 there are two regions, the 
BBXXB domain and the DRY motif, located in the 
third intracellular (i3) and second intracellular (i2) 
loops, respectively, which are needed to activate the 
signalling pathways mediated by this receptor subtype. 
Namely, the BBXXB domain, although being required 
in the subtype 5 downstream effectors generation, is 
not directly involved in interactions with Gi protein, 
since a mutation in the first BBXXB residue does not 
affect the receptor ability of inhibiting cAMP 
accumulation. Conversely, the DRY motif was found to 
be crucial in coupling with Gi protein, since mutations 
in the DRY sequence do not impair sst5-driven 
inhibition of cAMP production. However, both regions 
are necessary to mediate the other sst5 intracellular 
responses, such as cytoplasmic Ca2+ reduction and 
inhibition of ERK1/2 phosphorylation (Peverelli et al., 
2009). 
3. Tumorigenesis 
Tumorigenesis is a collection of complex genetic 
diseases characterized by multiple defects in the 
homeostatic mechanisms that regulate cell growth, 
proliferation and differentiation. In humans, several 
lines of evidence indicate that tumorigenesis is a 
multistep process which reflects genetic alterations that 
drive the progressive transformation of normal cells 
into highly malignant derivatives. Tumorigenesis is 
thought to require four to six stochastic rate-limiting 
mutation events to occur in the lineage of one cell. 
Hanahan and Weinberg (Hanahan and Weinberg, 2000) 
suggest that six cellular alterations, or hallmarks, 
collectively drive a population of normal cells to 
become a cancer. The six hallmarks are (i) self-
sufficiency in growth signals (SG), (ii) insensitivity to 
antigrowth signals (IA), (iii) evasion of apoptosis (EA), 
(iv) limitless replicative potential (LR), (v) sustained 
angiogenesis (SA), and (vi) tissue invasion and 
metastasis. Genetic instability (GI) is defined as an 
"enabling characteristic" that facilitates the acquisition 
of other mutations due to defects in DNA repair. These 
hallmarks form a candidate set of rules that underlie the 
transformation of a normal tissue to a cancerous one 
and are shared in common by most and perhaps all 
types of human tumors (Spencer et al., 2006). 
3.1 Antitumor actions of somatostatin and 
somatostatin analogs 
SS has been shown to display several biological actions 
which include inhibition of exocrine and endocrine 
secretions, gut motility, cell proliferation, cell survival 
and angiogenesis. SS analogs show antineoplastic and 
antiproliferative activity in many experimental in vivo 
and in vitro models and this activity is principally 
attributed to activation of sst2 and sst5. SS analogs 
treatment can be effective in the control of tumor 
growth in humans and in 37-82% of patients receiving 
SS analogs, as primary medical therapy, tumor 
shrinkage has been observed. The antiproliferative and 
antitumoral effects of SS analogs occur independently 
of their antisecretory and antihormonal effects. From 
these results we can infer that antisecretory and 
antitumor effects of SS and SS analogs are mediated by 
different receptors/signalling pathways and that the 
antiproliferative effect of these synthetic compounds 
may depend on tumor ssts profile, but also on the 
specific target cell intracellular signalling (Pyronnet et 
al., 2008). 
SS and SS analogs can control tumor development and 
progression/metastatization by two separate 
mechanisms: direct actions, mediated by the ssts, and 
indirect actions, independent of the receptors. 
3.1.1 Direct somatostatin antitumor actions 
Direct effects of SS and its analogs on tumor cell 
growth and spread derive from interaction with specific 
tumor cell membrane receptors. The direct 
antiproliferative actions include inhibition of 
autocrine/paracrine growth-promoting hormone/growth 
factor synthesis, arrest of cell division (by blockade of 
growth factor-mediated mitogenic signals), suppression 
of cell invasion and induction of apoptosis 
(programmed cell death) (Pyronnet et al., 2008). The 
exact antitumoral mechanism initiated by SS analogs 
depends on the tumor cell type and the ssts to which it 
binds. In this way, each receptor subtype is able to 
mediate different biological actions (Susini and 
Buscail, 2006). 
Cell cycle arrest is mediated by interaction of SS with 
its five receptors and the consequent initiation of 
several intracellular signalling pathways, which are 
either activated or inhibited according to the sst 
subtype, the downstream recruited enzyme and cell 
environment. These pathways include activation of 
tyrosine kinases (JAK, c-src) and tyrosine phosphatases 
(SHP1, SHP2, PTP), activation/inhibition of nitric 
oxide synthase/cGMP-dependent protein kinase, 
Ras/ERK pathway and inhibition of PI3 kinase/Akt 
pathway, which in turn lead to induction of the cyclin-
dependent kinase inhibitor p27kip1 or p21Cip1 and cell 
cycle arrest (Pyronnet et al., 2008). SS also induces cell 
growth inhibition through restoration of functional gap 
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junctions. These structures are composed of connexins 
and play a pivotal role in maintaining the differentiated 
state and cell-contact inhibition. Actually, in most 
cancer cells, it has been observed an impaired 
expression of connexins (Lahlou et al., 2005). It has 
been demonstrated that SS is also a potent anti-
migratory and anti-invasive agent for various tumor 
cells. Inhibition of cell invasion occurs through 
molecular mechanisms which are cell type specific and 
depend on sst expression pattern, on sst effector 
coupling as well as on the signalling cascade involved 
in target cells (Pola et al., 2003). 
SS analogs are also thought to inhibit cell proliferation 
by inducing apoptosis. The receptor subtypes primarily 
involved in SS-induced apoptosis are sst3 and sst2. 
Apoptotic effect is achieved by regulation of the two 
main signalling pathways, the cell-extrinsic pathway 
(triggered by death receptors) and the cell-intrinsic 
pathway (also called the mitochondrial pathway) 
(Pyronnet et al., 2008; Florio, 2008b). 
SS and its chemically designed analogs are potential 
therapeutic agents, in particular for the treatment of 
endocrine diseases that cause hormone hypersecretory 
syndromes. SS and its commercially available analogs 
exert antisecretory and antiproliferative effects by 
interacting with one or more of the five ssts, which then 
trigger various intracellular signalling pathways 
according to the tissue, thus possibly leading to 
different actions. The tissue expression patterns of ssts, 
the binding profile of agonists and ssts effector 
coupling confer functional and therapeutic specificity 
to ligand activity (Zatelli and degli Uberti, 2009). 
The two SS analogs currently used in the clinics are 
Octreotide and Lanreotide. They have demonstrated 
efficacy in reducing GH and IGF-1 levels in up to 60% 
of patients with acromegaly and therefore have been 
widely used in the treatment of GH hypersecretion 
(Shimon et al., 1997). The main pharmacological target 
of these compounds is sst2, the receptor subtype which 
is the most frequently expressed in human GH-
secreting pituitary adenomas, but they also bind, with a 
lesser affinity, to sst5. However, a significant 
proportion of patients with acromegaly is resistant to 
the treatment with ocreotide. 
Pasireotide (SOM-230), a compound that interacts with 
multiple ssts (sst1-2-3-5) is able to inhibit GH secretion in 
octreotide-resistant pituitary adenomas, representing a 
potential therapy for octreotide-resistant acromegaly 
patients (Petersenn et al., 2010). The efficacy of 
pasireotide in overcoming octreotide resistance has 
been attributed to its ability of binding to all ssts and, in 
particular, to its greater affinity for sst5, which is up-
regulated in such tumors. This ssts multiligand 
compound showed in vitro a significant reduction of 
cell viability in many non-functioning pituitary 
adenomas (NFPAs) probably through the inhibition of 
VEGF secretion. Several results suggested that 
pasireotide could be a potential therapeutic agent for 
conditions characterized by an excess of ACTH. In 
patients with Cushing's disease, the administration of 
pasireotide decreased urinary free cortisol levels and 
significantly improved symptoms associated with the 
disease. Moreover, in ACTH-secreting pituitary tumor 
cells, pasireotide reduced ACTH secretion and cell 
proliferation (Bode et al., 2010). NFPAs represent a 
possible therapeutic target also for selective sst1 
agonists as these tumors have been demonstrated to 
express sst1. The sst1 agonist BIM-23926 has exhibited 
antisecretory and antiproliferative effects in a group of 
NFPAs in vitro. Moreover, several findings support the 
hypothesis that chimeric ssts/DR agonists can be 
effective in suppressing in vitro cell proliferation in the 
majority of NFPAs. Indeed, BIM-23A387, a chimeric 
sst2/DR2 selective agonist inhibits cell viability in most 
NFPA primary cultures, as well as BIM-23A760, a 
compound with high affinity for DR2, sst2 and sst5 
significantly suppresses DNA synthesis in the 60% of 
the NFPA cultures tested (Florio et al., 2008). 
It has been observed that SS and its analogs can 
decrease plasma calcitonin levels and improve 
symptoms in patients with medullary thyroid carcinoma 
(MTC), but their antiproliferative effects remain 
controversial. As a matter of fact, in TT cells, a human 
MTC cell line expressing all ssts, sst2 activation leads to 
inhibition of DNA synthesis and cell proliferation, 
whereas sst5 activation has an opposite effect. Thus, we 
can infer that sst2 and sst5 agonists can antagonize the 
activity of one another in contrast to what happens in 
pituitary adenomas. Potent sst1-selective ligands (BIM-
23296 and BIM-23745) could have a therapeutic role in 
MTC because they are effective in reducing DNA 
synthesis, the viability of TT cells, calcitonin secretion 
and gene expression (Zatelli et al., 2006). 
Ssts are also highly expressed in most neuroendocrine 
tumors with a variable expression patterns. Treatment 
with Octreotide and Lanreotide is ineffective in 
inhibiting hormone secretion in some patients with 
neuroendocrine tumors because they develop 
tachyphylaxis. Conversely, pasireotide has shown a 
considerable reduction of symptoms in the majority of 
patients with metastatic gastroenteropancreatic 
endocrine tumors (Desai et al., 2009). 
Experimental data on prostate cancer showed that four 
(sst1-2-3-5) out of five ssts receptors were found to be 
expressed in the LNCaP cell line, an in vitro model of 
human androgen-dependent PCa. Their activation by 
selective SS agonists resulted in a significant anti-
proliferative effect with a peculiar pattern according to 
receptor subtype, ligand affinity and, possibly, receptor 
dimerization. Moreover, such treatments were also able 
to modulate the profile of the IGF system, known to be 
involved in PCa progression. Interestingly, these data 
provide strong evidence for an inhibitory role of sst1 
activation on PCa cell proliferation, suggesting that SS 
agonists with enhanced sst1 affinity and selectivity may 
have great potentiality as pharmacological tools for at 
least androgen-dependent PCa treatment. In addition, 
the antiproliferative effect of sst1 and sst5 mono-
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specific agonists may be due, at least in part, to the 
inhibition of IGF-I secretion (Ruscica et al., 2010). 
3.1.2 Indirect somatostatin antitumor mechanisms 
Indirect antitumor effects of SS include suppression of 
synthesis or/and release of growth factors and growth-
promoting hormones such as insulin, prolactin, IGF-1, 
epidermal growth factor (EGF), transforming growth 
factor- (TGF-), gastrin, cholecystokinin (CCK) and 
GH. 
Several experimental in vitro and in vivo results 
indicate that another indirect action of SS and SS 
analogs on tumor growth may be the inhibition of 
angiogenesis. Angiogenesis, the formation of new 
blood vessels from an existing capillary network, is 
necessary for tumor neovascularization, which is 
essential for tumor growth, invasion and for 
dissemination of metastasis. By limiting the blood 
supply, tumor growth can be effectively controlled 
(Kvols and Woltering, 2006). SS and SS analogs exert 
antiangiogenic actions through different mechanisms 
like suppression of endothelial cell proliferation and 
arrest of monocyte and endothelial cell migration. 
Normal endothelial cells lack sst2 receptors and the 
expression of this receptor subtype on endothelial cells 
uniquely appears as they proliferate to form new blood 
vessels (Kvols and Woltering, 2006). So, the inhibition 
of angiogenesis may result from the up-regulation of 
sst2 during the angiogenic switch from resting to 
proliferating endothelium. However, other ssts such as 
sst3 and sst5 may also play a role. At the molecular 
level, this effect results from SS-mediated inhibition of 
MAP kinase activity and endothelial NO synthase 
(eNOS) activity. Another mechanism by which SS 
analogs suppress angiogenesis is through a broad 
inhibition of both the release and the effect of growth 
factors, some of which are angiogenic, including 
vascular endothelial growth factor (VEGF), platelet-
derived growth factor, IGF-1 and basic fibroblast 
growth factor. These growth factors, secreted by tumor 
cells and infiltrating inflammatory cells, stimulate 
endothelial and smooth muscle cell proliferation and 
migration, important processes in angiogenesis (Zatelli 
et al., 2007). 
4. Somatostatin receptor activation 
and tumorigenesis: future 
directions 
According to the evidence reported in the present 
paper, a specific pattern of ssts activation seems to elicit 
important antitumoral actions with potential relevance 
to some solid tumors expressing these receptor 
isoforms. In addition to the well-established anti-
secretory effects, which may affect the cancer-
associated paraneoplastic syndrome as well as the 
possible autotrophic actions of tumor-produced 
secretory proteins, a consistent body of data indicates 
that stimulation of tumor-expressed ssts results in a  
multi-step restrain of tumorigenesis. These mechanisms 
thus deserve further exploitation with the aim of 
validating novel therapeutic approaches to cancer. 
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